Navigation Links
Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
Date:1/29/2008

fessionalism in the sports nutrition sector.

The final set of results from Millennium's sponsored Division 1 Football trial at Rutgers University have shown that Surgex(TM) had a significant effect on recovery markers including testosterone:cortisol ratios compared to a market leading sports beverage on the market. "Along with our previous statistically significant improvements in body composition and strength parameters, the recovery marker data continues to validate Surgex(TM) as an important nutritional adjunct for the athlete" states Mr. Germano. "As we have seen in the medical market, Surgex is now able to offer the athlete a product that will assist in recovery in efforts to improve performance. In addition, our participation in the BSCG program continues to set us apart from the competition."

The continued usage and acceptability of Surgex(TM) by Professional, Olympic, and Collegiate athletes is providing the valuable market information which will allow Millennium to develop the best strategy to commercialize Surgex(TM), expected in Q3 of 2008.

About Surgex(TM):

Surgex(TM) (http://www.surgexsports.com) was created from Millennium's extensive experience providing advanced nutritional formulas to some of the most prestigious medical institutions throughout the United States The proprietary Surgex(TM) formula intends to meet the growing demand of elite level Professional, Olympic and amateur athletes and their coaches looking for nutritional support in a marketplace dominated by products with no clinical proof of benefit, unsubstantiated claims, excess protein, stimulants, and banned substances.

In double blind placebo controlled trials at the Rutgers University Human Performance Lab Surgex(TM) significantly outperformed leading competitive products by assisting in reducing the damaging effects of exercise by improving peak power outputs, lowering oxidative stress/inflamma
'/>"/>

SOURCE Millennium Biotechnologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
4. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
5. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
7. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
9. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Sinovac Biotech Ltd. (NASDAQ: SVA ... , today announced the results of the Company,s 2014 Annual ... Beijing , PRC. The required quorum, a majority ... The Company,s shareholders approved the following proposals:  , ... , Simon Anderson , Kenneth Lee and ...
(Date:8/27/2014)... , Aug. 27, 2014  AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... announced that senior management will be participating at the ... the Morgan Stanley Global Healthcare Conference.  Details of the ... One on One Conference Date: Wednesday September 3 rd ...
(Date:8/26/2014)... KUALA LUMPUR, Malaysia , Aug. 27, 2014 ... penetration of health insurance are fuelling the demand ... . With the rise of medical tourism, the ... is further increasing. The market will continue its ... increasingly vulnerable to age-related and non-communicable diseases, compelling ...
Breaking Medicine Technology:Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 2Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 3Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 4
... HAYWARD, Calif., Dec. 14, 2010 Anthera Pharmaceuticals, Inc. ... drugs to treat serious diseases associated with abnormal auto-immune ... in the UK, to manufacture the large scale GMP ... peptibody in development for a number of autoimmune diseases. ...
... announces that a new market research report is available ... Global Markets http://www.reportlinker.com/p0341186/Antiemetics-Technologies-and-Global-Markets.html ... billion in 2009.  There was a little setback seen ... economy and competition within brands and generics.  The market ...
Cached Medicine Technology:Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent 2Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent 3Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent 4Reportlinker Adds Antiemetics: Technologies and Global Markets 2Reportlinker Adds Antiemetics: Technologies and Global Markets 3Reportlinker Adds Antiemetics: Technologies and Global Markets 4Reportlinker Adds Antiemetics: Technologies and Global Markets 5Reportlinker Adds Antiemetics: Technologies and Global Markets 6Reportlinker Adds Antiemetics: Technologies and Global Markets 7Reportlinker Adds Antiemetics: Technologies and Global Markets 8Reportlinker Adds Antiemetics: Technologies and Global Markets 9Reportlinker Adds Antiemetics: Technologies and Global Markets 10Reportlinker Adds Antiemetics: Technologies and Global Markets 11Reportlinker Adds Antiemetics: Technologies and Global Markets 12Reportlinker Adds Antiemetics: Technologies and Global Markets 13
(Date:8/27/2014)... of clinical trial participation in the largest ongoing observational ... are not representative of the larger patient base, according ... Dr. Jay Udell. The study authors call into question ... population, and suggest the use of broader enrollment criteria ... "We know that clinical trials can be tremendously expensive ...
(Date:8/27/2014)... Los Angeles, CA (PRWEB) August 27, 2014 ... everyone. To do this, Jaha invested in creating the industry’s ... motivation by adding functions that no other apps possess. ... with a tracker that differentiates in three simple steps: locate, ... will launch on Tuesday, Aug 26, 2014 to garner support ...
(Date:8/27/2014)... 2014 The Global and China Maleic ... the current state of the Maleic Anhydride industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/27/2014)... Do brands know what consumers think of their marketing ... on the topic Sept. 16 when it reveals the results ... Association and the Association of National Advertisers . ... learn what types of marketing messages are the most likable ... decision. While the survey focuses on consumer reaction to radio ...
(Date:8/27/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... PRODUCTS , the global market for advanced orthopedic technology ... to $42.2 billion by 2019, with a compound annual ... New technologies and an increasingly older population are two ... While there are many conventional and generally less expensive ...
Breaking Medicine News(10 mins):Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Jaha, Inc. The Most Affordable Fitness Band in the Market Released on Kickstarter 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:CRN Set To Release Poll Results On What Marketing Tactics Prompt Consumers To Buy 2Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 2Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 3
... say the autism rate in the U.S. is now 1 in ... country know those statistics are inaccurate. , Misdiagnosis is the hottest ... misdiagnosed with autism , a label parents are often pushed ... October 9-11, in 90+ cities around the world, parents will gather ...
... 2009 Golden Apple Awards , CHICAGO, Oct. ... state and local dental societies across the nation with the ... in its 21st year, recognizes outstanding achievement in dental society ... Apple Awards will be presented through the end of the ...
... at Fred Hutchinson Cancer Research Center, Group Health ... of Public Health and Pharmacy have been selected ... million in federal stimulus funding for comparative-effectiveness research ... national hub for conducting such research, which aims ...
... National Institutes of Health announced today a second phase ... funds for 19 research consortia. The Rare Diseases Clinical ... will be awarded a total of just over $117 ... with the new funding will explore the natural history, ...
... widely used for applications that include inventory management, ... luggage security. More recently, these systems have found ... equipment assets and staff members. However, there ... which manufacturers of RFID equipment or medical devices ...
... College of Preventive Medicine (ACPM) supports the recommendations of ... care providers should screen all adults for depression, and ... systems in place to ensure the accurate diagnosis and ... opportunities to identify depression are in the clinics of ...
Cached Medicine News:Health News:Autism Stats Exaggerated: Parents Pushing Back This Weekend 2Health News:ADA Honors State and Local Dental Societies for Their Outreach Programs 2Health News:$16M in stimulus funding launches Seattle as a hub of comparative-effectiveness research in cancer 2Health News:$16M in stimulus funding launches Seattle as a hub of comparative-effectiveness research in cancer 3Health News:$16M in stimulus funding launches Seattle as a hub of comparative-effectiveness research in cancer 4Health News:$16M in stimulus funding launches Seattle as a hub of comparative-effectiveness research in cancer 5Health News:NIH announces expansion of Rare Diseases Clinical Research Network 2Health News:NIH announces expansion of Rare Diseases Clinical Research Network 3Health News:NIH announces expansion of Rare Diseases Clinical Research Network 4Health News:NIH announces expansion of Rare Diseases Clinical Research Network 5Health News:NIH announces expansion of Rare Diseases Clinical Research Network 6Health News:NIH announces expansion of Rare Diseases Clinical Research Network 7Health News:NIH announces expansion of Rare Diseases Clinical Research Network 8Health News:GTRI is developing protocols for testing effects of RFID systems on medical devices 2Health News:GTRI is developing protocols for testing effects of RFID systems on medical devices 3
Bio-Rad's Genetic Systems HIV-1/HIV-2 PLUS O EIA is a unique assay that detects the broadest range of HIV....
The humidity chamber maintains a moist environment during immunostaining procedures as well as other laboratory procedures requiring controlled incubation steps....
Thermostatically controlled, large capacity surface to quickly evaporate water and solvents from slides and mounting media....
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: